Affiliate disclosure: This article contains affiliate links. If you buy through them, we may earn a commission at no extra cost to you. This does not influence our assessment of the evidence below.
Evidence rating: Moderate — the two headline botanicals have randomized human trials, but the outcomes they move are lab markers more than the scale
What HepatoBurn Claims To Be
HepatoBurn is sold as a liver-first weight formula. The pitch is that stubborn body fat is downstream of a sluggish, fat-loaded liver, and that supporting liver function is therefore the lever worth pulling before you touch anything else.
The framing is unusual for a diet supplement, and it is not baseless. Fat accumulation in the liver genuinely tracks with insulin resistance and disordered lipid handling, and it has become one of the most-studied targets in metabolic nutrition research. Whether a capsule meaningfully shifts that is the actual question.
What’s Actually In It
HepatoBurn splits its label into two proprietary blends:
Liver Purification Complex — silymarin (milk thistle extract), betaine (trimethylglycine), berberine, molybdenum, glutathione
Liver Fat-Burning Complex — resveratrol, camellia sinensis (green tea extract), genistein, chlorogenic acid, choline
Ten named ingredients is more disclosure than many competitors offer. What you do not get is the amount of any of them. Both complexes are listed as proprietary blends, so the per-ingredient milligrams are not published. That matters here more than usual, because the trials below used specific doses — berberine at 1,500 mg/day, for example — and there is no way to check the label against them.
What The Research Shows
According to PubMed, the strongest ingredient signal in this formula comes from silymarin and berberine.
Silymarin has the deepest evidence base, and it is mostly about liver enzymes and lipids. A systematic review and meta-analysis pooling 26 randomized controlled trials across 2,375 patients with fatty liver found that silymarin significantly lowered ALT and AST (the standard liver-injury enzymes), reduced total cholesterol, triglycerides and LDL, raised HDL, and improved fatty liver index scores. A subset with biopsy data showed improved hepatic steatosis on histology. DOI
But silymarin’s metabolic effects are shakier than that sounds. A separate 2025 meta-analysis of six RCTs (673 participants) looking specifically at insulin resistance found only a modest improvement in HOMA-IR overall, no effect at all on fasting insulin — and, notably, no effect on insulin resistance in the fatty-liver subgroup. The authors’ own conclusion was that evidence for silymarin improving these markers is limited. That is a direct counterweight to the more enthusiastic reading above. DOI
Berberine produced real but narrow changes in a placebo-controlled trial. Seventy adults with metabolic dysfunction-associated fatty liver disease took 1,500 mg/day of berberine or placebo for 12 weeks in a randomized, double-blind design. The berberine group showed significantly lower ALT and total cholesterol versus placebo. Trunk fat fell in both groups, and there were no significant between-group differences in the other lipid or glucose measures. The authors called berberine promising but explicitly said longer studies are needed. DOI
Berberine is being taken seriously enough to be developed as a drug. A phase 2 randomized study of berberine ursodeoxycholate in 100 patients with presumed metabolic steatohepatitis found 52% of treated patients hit the MRI liver-fat response threshold versus 24% on placebo, with dose-dependent improvement across biomarkers. Worth reading carefully, though: that is a specific pharmaceutical salt at pharmaceutical dosing, not the berberine in a proprietary blend. DOI
The remaining ingredients — resveratrol, green tea, chlorogenic acid — have been studied in this space too, but a 2025 scoping review that catalogued 131 primary studies of bioactive substances for fatty liver found the field heterogeneous and the clinical efficacy of most compounds still unestablished. DOI
The Honest Verdict
What holds up: Silymarin and berberine are not filler. Both have randomized human data, both repeatedly lower liver enzymes and improve lipid panels, and the “support the liver” premise reflects an area researchers are actively pursuing rather than a marketing invention. Choline and betaine also have well-described roles in hepatic fat export.
What doesn’t: The gap between “improves ALT and cholesterol” and “burns stubborn body fat” is wide, and the trials do not close it. The berberine trial saw trunk fat drop in the placebo group too. The silymarin insulin-resistance analysis found nothing in fatty-liver patients. And the proprietary blends make it impossible to know whether you are getting anything near the 1,500 mg of berberine that was actually tested — a formula splitting ten ingredients across two blends in a single daily capsule is unlikely to be.
Who this makes sense for: Someone whose interest is metabolic and liver markers, who already has diet and movement in hand, and who treats this as a possible small addition rather than the mechanism of weight loss. Ask the seller for per-ingredient amounts before buying.
Who should skip it: Anyone expecting fat loss without changing anything else. Also anyone on prescription medication — berberine is a meaningful inhibitor of drug-metabolizing enzymes and interacts with a long list of drugs, so this is a conversation with your prescriber, not a solo decision. Anyone with diagnosed liver disease should be managing it with a physician.
Check current pricing and availability
View HepatoBurn on the official site
This article is for informational purposes only and is not medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration. Talk to your physician before starting any supplement, especially if you have a diagnosed condition or take medication.
Research cited via PubMed: